PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

NCT ID: NCT04149535

Last Updated: 2023-02-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-07

Study Completion Date

2022-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the risk of peri-procedural stroke (≤72 hours) after transcatheter aortic valve replacement (TAVR).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAVR with Sentinel

Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.

Group Type EXPERIMENTAL

Sentinel® Cerebral Protection System

Intervention Type DEVICE

cerebral embolic protection system

TAVR without Sentinel

Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sentinel® Cerebral Protection System

cerebral embolic protection system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has documented aortic valve stenosis and is treated with an approved TAVR device via transfemoral access
* Subject has the recommended artery diameter at the site of filter placement per the Sentinel® Cerebral Protection System Instructions For Use: 9-15 mm for the brachiocephalic artery and 6.5-10 mm in the left common carotid artery.
* Subject (or legal representative) provides written informed consent.

Exclusion Criteria

* Subject has arterial stenosis \>70% in either the left common carotid artery or the brachiocephalic artery.
* Subject's brachiocephalic or left carotid artery reveals significant stenosis, ectasia, dissection, or aneurysm at the aortic ostium or within 3 cm of the aortic ostium.
* Subject has compromised blood flow to the right upper extremity.
* Subject has access vessels with excessive tortuosity.
* Subject has uncorrected bleeding disorders.
* Subject is contraindicated for anticoagulant and antiplatelet therapy.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Samir Kapadia, MD

Role: PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tucson Medical Center

Tucson, Arizona, United States

Site Status

Cedars Sinai Medical Center

Los Angeles, California, United States

Site Status

University of California, Davis Medical Center

Sacramento, California, United States

Site Status

Kaiser Foundation Hospital - San Francisco

San Francisco, California, United States

Site Status

Los Robles Regional Medical Center

Thousand Oaks, California, United States

Site Status

South Denver Cardiology Associates PC and Swedish medical center

Littleton, Colorado, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

Medstar Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Intercoastal Medical Group

Sarasota, Florida, United States

Site Status

Tampa General Hospital

Tampa, Florida, United States

Site Status

Piedmont Hosptial

Atlanta, Georgia, United States

Site Status

Wellstar

Marietta, Georgia, United States

Site Status

St. Johns Hospital

Springfield, Illinois, United States

Site Status

Community Munster

Munster, Indiana, United States

Site Status

Mercy Hospital Medical Center

Des Moines, Iowa, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Lahey Clinic Hospital

Burlington, Massachusetts, United States

Site Status

Sparrow Hospital

Lansing, Michigan, United States

Site Status

Abbott Northwestern Hospital

Minneapolis, Minnesota, United States

Site Status

Research Medical Center

Kansas City, Missouri, United States

Site Status

Creighton - Bergan Cardiology

Omaha, Nebraska, United States

Site Status

Englewood Medical Center

Englewood, New Jersey, United States

Site Status

Jersey Shore University Medical Center

Neptune City, New Jersey, United States

Site Status

Kaleida Health

Buffalo, New York, United States

Site Status

North Shore University Hospital

Manhasset, New York, United States

Site Status

NYU Winthrop

Mineola, New York, United States

Site Status

Wake Forest University School of Medicine

Winston-Salem, North Carolina, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

Oregon Health Sciences University

Portland, Oregon, United States

Site Status

Lankenau

Wynnewood, Pennsylvania, United States

Site Status

Baptist Memorial

Memphis, Tennessee, United States

Site Status

Centennial Medical Center

Nashville, Tennessee, United States

Site Status

Vanderbilt

Nashville, Tennessee, United States

Site Status

Heart Hospital of Austin

Austin, Texas, United States

Site Status

Baylor Heart and Vascular

Dallas, Texas, United States

Site Status

The Methodist Hospital

Houston, Texas, United States

Site Status

The Heart Hospital Baylor Plano

Plano, Texas, United States

Site Status

Baylor Scott and White

Round Rock, Texas, United States

Site Status

Methodist Healthcare System of San Antonio dba Methodist Hospital

San Antonio, Texas, United States

Site Status

Aurora St. Luke's Medical Center

Milwaukee, Wisconsin, United States

Site Status

Monash Medical Center

Clayton, Victoria, Australia

Site Status

The Prince Charles Hospital

Chermside, , Australia

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Rigshospitalet

Copenhagen, , Denmark

Site Status

CHU La Timone Hospital

Marseille, , France

Site Status

Clinique Pasteur

Toulouse, , France

Site Status

Heart Center Leipzig

Bad Segeberg, , Germany

Site Status

Herzzentrum Dresden GmbH

Dresden, , Germany

Site Status

University Hospital Frankfurt

Frankfurt, , Germany

Site Status

Universitaetsklinikum Schleswig-Holstein

Lübeck, , Germany

Site Status

LMU Klinikum der Universität München

Münich, , Germany

Site Status

Universitaetsklinikum Ulm

Ulm, , Germany

Site Status

Policlinico San Donato

San Donato, Milanese, Italy

Site Status

Maria Cecilia Hospital SPA

Cotignola, , Italy

Site Status

Fondazione Centro San Raffaele

Milan, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Denmark France Germany Italy

References

Explore related publications, articles, or registry entries linked to this study.

Makkar RR, Gupta A, Waggoner TE, Horr S, Karha J, Satler L, Stoler RC, Alvarez J, Sakhuja R, MacDonald L, Modolo R, Leon MB, Linke A, Kapadia SR. Cerebral Embolic Protection by Geographic Region: A Post Hoc Analysis of the PROTECTED TAVR Randomized Clinical Trial. JAMA Cardiol. 2025 Jan 1;10(1):17-24. doi: 10.1001/jamacardio.2024.4278.

Reference Type DERIVED
PMID: 39471309 (View on PubMed)

Kapadia SR, Makkar R, Leon M, Abdel-Wahab M, Waggoner T, Massberg S, Rottbauer W, Horr S, Sondergaard L, Karha J, Gooley R, Satler L, Stoler RC, Messe SR, Baron SJ, Seeger J, Kodali S, Krishnaswamy A, Thourani VH, Harrington K, Pocock S, Modolo R, Allocco DJ, Meredith IT, Linke A; PROTECTED TAVR Investigators. Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement. N Engl J Med. 2022 Oct 6;387(14):1253-1263. doi: 10.1056/NEJMoa2204961. Epub 2022 Sep 17.

Reference Type DERIVED
PMID: 36121045 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S2453

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The PROTEMBO SF Trial
NCT03325283 COMPLETED NA
GORE Embolic Protection With Reverse Flow
NCT00594100 COMPLETED PHASE3